Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXAZOSIN MESYLATE vs MICARDIS HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
Hypertension,Benign prostatic hyperplasia (BPH),Off-label: Pheochromocytoma (preoperative management), Raynaud's phenomenon, ureteral stones
Treatment of hypertension, alone or in combination with other antihypertensive agents
Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
Terminal elimination half-life is approximately 22 hours. This long half-life supports once-daily dosing for hypertension and benign prostatic hyperplasia.
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
Extensively metabolized in the liver via O-demethylation and hydroxylation, primarily by CYP3A4.
Telmisartan is primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A8; it is not metabolized by CYP450 enzymes. Hydrochlorothiazide is not extensively metabolized; it is eliminated unchanged in the urine.
Approximately 63% of the dose is excreted in feces via biliary elimination, and about 9% is excreted unchanged in urine. The remainder is metabolized, with metabolites excreted in urine and feces.
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Approximately 98-99% bound to plasma proteins, primarily albumin.
Telmisartan: >99.5% bound primarily to albumin and α1-acid glycoprotein. Hydrochlorothiazide: 40-68% bound to albumin.
0.5-1.5 L/kg, indicating extensive distribution into tissues and extravascular spaces.
Telmisartan: 500 L (≈7 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: 0.8-1.2 L/kg, confined to extracellular fluid.
Oral bioavailability is approximately 65% due to first-pass metabolism. Food does not significantly affect absorption.
Telmisartan: absolute oral bioavailability ≈42-58% (dose-dependent). Hydrochlorothiazide: oral bioavailability ≈65-75%.
No dose adjustment needed for renal impairment. Doxazosin is minimally renally excreted.
Contraindicated if GFR <30 m L/min. No adjustment needed for GFR 30-89 m L/min. Monitor renal function.
Contraindicated in severe hepatic impairment (Child-Pugh C). In mild-moderate impairment (Child-Pugh A or B), use with caution; consider starting at 1 mg once daily and titrate slowly.
Contraindicated in severe hepatic impairment (Child-Pugh C). Caution and possible dose reduction in mild-to-moderate impairment; maximum 40 mg/12.5 mg daily.
Safety and effectiveness in pediatric patients have not been established. Not recommended for use in children.
Safety and efficacy not established in pediatric patients (<18 years).
Use cautiously due to increased risk of orthostatic hypotension, dizziness, and falls. Start at 1 mg once daily, titrate slowly. Monitor blood pressure carefully.
No initial dose adjustment required; monitor blood pressure and renal function, especially with concurrent diuretic therapy.
None
None
Orthostatic hypotension and syncope, especially with first dose ('first-dose effect'),Risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery,Hepatic impairment may decrease metabolism,Priapism (rare),Drowsiness/somnolence, caution with operating machinery
Avoid use in pregnancy; can cause fetal harm when administered to a pregnant woman (discontinue as soon as possible when pregnancy is detected),May cause symptomatic hypotension in patients with volume or salt depletion,Monitor renal function; may cause acute renal failure, especially in patients with renal artery stenosis,Monitor serum electrolytes; risk of electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia) due to hydrochlorothiazide,May exacerbate or activate systemic lupus erythematosus,May cause acute angle-closure glaucoma (due to hydrochlorothiazide),May cause hypersensitivity reactions, including anaphylaxis and angioedema (telmisartan),Use with caution in patients with hepatic impairment (telmisartan),Use with caution in patients with diabetes or impaired renal function; may increase risk of renal impairment when used with NSAIDs or COX-2 inhibitors,Monitor for hyperuricemia and gout,May cause photosensitivity reactions
Hypersensitivity to doxazosin or quinazolines,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension,Severe hepatic impairment
Hypersensitivity to telmisartan, hydrochlorothiazide, or any component of the formulation,Anuria (due to hydrochlorothiazide),Concomitant use with aliskiren in patients with diabetes mellitus,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment
Avoid grapefruit and grapefruit juice as they may increase drug levels. No other significant food interactions.
Avoid high-potassium foods (bananas, oranges, tomatoes, spinach, salt substitutes) due to telmisartan's potassium-sparing effect. Hydrochlorothiazide may cause hypomagnesemia and hypokalemia; ensure adequate intake of magnesium-rich foods (nuts, whole grains) and potassium-rich foods (if not contraindicated). Avoid excessive alcohol intake which can increase hypotensive effect.
FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and well-controlled studies in pregnant women. Potential fetal risks include possible hypotension and reduced placental perfusion, especially in the second and third trimesters. Use only if potential benefit justifies risk.
First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligohydramnios, skull ossification defects, hypotension, and anuria. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Doxazosin is excreted in human milk. The milk-to-plasma ratio is not reported. Caution is advised; monitor infant for signs of hypotension. Consider alternative therapy in hypertensive mothers during breastfeeding.
Telmisartan is excreted in human milk in very low concentrations; M/P ratio unknown for telmisartan. Hydrochlorothiazide is excreted in breast milk; M/P ratio approximately 1.6. Avoid breastfeeding due to potential for adverse effects on the infant, including electrolyte disturbances and hypotension.
No specific dose adjustments recommended for pregnancy. However, consider increased clearance and volume of distribution, especially in third trimester. Start with lowest effective dose (1 mg/day) and titrate based on blood pressure response. May require more frequent monitoring.
No dose adjustment data specific to pregnancy for Micardis HCT. Due to risk of fetal harm, use is contraindicated in pregnancy; discontinue as soon as pregnancy is detected. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may theoretically require dose adjustment, but no established guidelines.
First-dose syncope can occur; start with 1 mg at bedtime. Titrate slowly based on standing blood pressure. Monitor for orthostatic hypotension, especially in elderly. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery. Also used for benign prostatic hyperplasia (BPH) and hypertension.
MICARDIS HCT (telmisartan/hydrochlorothiazide) is a fixed-dose combination for hypertension not controlled on monotherapy. Monitor renal function, electrolytes (especially potassium and sodium), and volume status. Avoid in severe renal impairment (Cr Cl <30 m L/min) and anuria. Assess for hypotension, particularly in volume-depleted patients. Use with caution in hepatic impairment, diabetes, and history of angioedema. May cause fetal harm in pregnancy; discontinue as soon as possible. Telmisartan is not dialyzable.
Take the first dose at bedtime to minimize dizziness.,Avoid sudden standing; rise slowly from sitting or lying positions.,May cause drowsiness; do not drive until you know how the medication affects you.,Avoid alcohol, as it can increase dizziness and drowsiness.,Inform your surgeon if you are taking this drug before cataract surgery.,Do not skip doses or discontinue abruptly; consult your doctor.
Take exactly as prescribed; do not skip doses or take double doses.,Notify your doctor immediately if you become pregnant or plan to become pregnant.,Avoid alcohol, NSAIDs, and salt substitutes containing potassium.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, confusion, or decreased urination.,This medication may increase blood sugar; monitor if you have diabetes.
"Rifampicin is a potent inducer of cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of doxazosin. Concurrent use significantly increases doxazosin clearance, reducing its plasma concentration and thereby diminishing its antihypertensive effect. This interaction may lead to loss of blood pressure control, necessitating dose adjustment or alternative therapy."
"Clemastine, a first-generation antihistamine, is primarily metabolized by hepatic cytochrome P450 enzymes, including CYP2D6 and CYP3A4. Doxazosin, an alpha-1 adrenergic receptor antagonist used for hypertension and benign prostatic hyperplasia, can inhibit these CYP isoenzymes, potentially leading to reduced clemastine clearance and elevated plasma concentrations. This may increase the risk of clemastine-related adverse effects such as sedation, anticholinergic toxicity (e.g., dry mouth, urinary retention), and paradoxical CNS stimulation, especially in elderly or renally impaired patients."
"Doxazosin, an alpha-1 adrenergic receptor antagonist, blocks vasoconstriction mediated by catecholamines, thereby opposing the vasopressor effects of ritodrine, a beta-2 adrenergic agonist that also possesses alpha-adrenergic activity. This pharmacodynamic antagonism can reduce the efficacy of ritodrine in achieving uterine relaxation and may lead to inadequate tocolysis or increased risk of maternal hypotension. Clinically, the combination may result in diminished tocolytic response and potential cardiovascular instability."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXAZOSIN MESYLATE vs MICARDIS HCT, answered by our medical review team.
DOXAZOSIN MESYLATE is a Alpha-1 Blocker that works by Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.. MICARDIS HCT is a Antihypertensive Combination (ARB + Thiazide Diuretic) that works by Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXAZOSIN MESYLATE and MICARDIS HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXAZOSIN MESYLATE is: Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.. The standard adult dose of MICARDIS HCT is: One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXAZOSIN MESYLATE and MICARDIS HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXAZOSIN MESYLATE is classified as Category A/B. FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and . MICARDIS HCT is classified as Category C. First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligoh. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.